community download

IQVIA: Orphan Medicines Launch Excellence - Sustaining launch success as Orphan Medicines come of age

Launching orphan medicines excellently will become increasingly important over the next five years. More patients with rare diseases have pharmacotherapies available, and there are a growing number of disease-focused registries, increasing public and policy maker awareness, and significant R&D investment in pharmacotherapies and in digital technologies to support trials and treatment. A new frontier of challenge faces orphan medicines companies as the gap between orphan medicines and mainstream specialty products narrows. To understand how to succeed in launching an orphan medicine in the coming years, companies must learn from past launches and apply an orphan medicines-focused launch excellence framework for success.
 
Download the white paper, “Orphan Medicines Launch Excellence” to learn how pharmaceutical companies can optimize all the activities needed to take orphan medicines from clinical development to commercialization, including:
  • Three fundamental orphan medicine launch excellence challenges
  • Ways in which companies launching orphan medicines can learn from excellence in mainstream launches
  • Specific areas of focus that are crucial for orphan medicines launch excellence

Some quick details

Email Address:*
First name:*
Last name:*
Job Title:*
Company:*
Industry:
Country:*

Remember my details Information

Information
Remember my details
We place a 'cookie' on your computer so next time you visit us you don't need to fill in all these details


Privacy statement »
Manage your email preferences »
 

You will be emailed the document as an attachment (4,077Kb in size)